Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
EXEL - Exelixis, Inc.
Market Cap 6.62B P/E 43.28 EPS this Y 140.00% Ern Qtrly Grth 178.50%
Income 349.99M Forward P/E 22.11 EPS next Y -3.80% 50D Avg Chg 5.00%
Sales 2.01B PEG 1.53 EPS past 5Y 8.25% 200D Avg Chg 13.00%
Dividend N/A Price/Book 2.58 EPS next 5Y 11.00% 52W High Chg -8.00%
Recommedations 2.10 Quick Ratio 4.08 Shares Outstanding 285.25M 52W Low Chg 37.00%
Insider Own 1.72% ROA 8.51% Shares Float 237.99M Beta 0.54
Inst Own 87.47% ROE 15.06% Shares Shorted/Prior 12.69M/11.79M Price 20.34
Gross Margin 96.06% Profit Margin 17.38% Avg. Volume 2,466,459 Target Price 27.70
Oper. Margin 43.37% Earnings Date Oct 28 Volume 4,906,656 Change 3.62%
Healthcare | Biotechnology | United States
About Exelixis, Inc.

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Exelixis, Inc. News
11/20/24 Zacks.com featured highlights Amazon, Maplebear, Exelixis and Doximity
11/12/24 ADMA Biologics Inc (ADMA) Hits Fresh High: Is There Still Room to Run?
11/11/24 Vericel Stock Sees RS Rating Shoot Higher
11/11/24 What Makes Exelixis (EXEL) a Strong Momentum Stock: Buy Now?
11/11/24 Here's Why Exelixis (EXEL) is a Strong Momentum Stock
11/07/24 Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November
11/07/24 Here's Why Exelixis (EXEL) is a Strong Value Stock
11/05/24 Here is Why Growth Investors Should Buy Exelixis (EXEL) Now
11/05/24 Earnings Estimates Rising for Exelixis (EXEL): Will It Gain?
11/05/24 EXEL vs. CSLLY: Which Stock Should Value Investors Buy Now?
11/04/24 Exelixis (EXEL) Reliance on International Sales: What Investors Need to Know
11/03/24 3 Magnificent Stocks Under $100 to Buy in November
11/01/24 Exelixis, Inc. Just Recorded A 18% EPS Beat: Here's What Analysts Are Forecasting Next
10/31/24 Exelixis price target raised to $36 from $33 at Piper Sandler
10/30/24 Q3 2024 Exelixis Inc Earnings Call
10/30/24 Exelixis Beats on Q3 Earnings and Sales, Raises Annual Outlook
10/30/24 Exelixis Inc (EXEL) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
10/29/24 Exelixis (EXEL) Q3 2024 Earnings Call Transcript
10/29/24 Exelixis (EXEL) Reports Q3 Earnings: What Key Metrics Have to Say
10/29/24 Exelixis (EXEL) Q3 Earnings and Revenues Beat Estimates
EXEL Chatroom

User Image UncleStock Posted - 16 hours ago

$SIGA $HRMY $INVA $EXEL suggested for Pharmaceuticals and Biotechnology - value screen: https://zpr.io/NGP6QnBCdEbN

User Image Lennox_Michael Posted - 17 hours ago

$CTLT $EXEL LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?

User Image MarkoPo Posted - 19 hours ago

[ $CTLT $EXEL] LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?

User Image jeffmeredith Posted - 1 day ago

$VRNA $EXEL Among the few bios that don’t look like total crud

User Image WallStJesus Posted - 1 day ago

$EXEL BULLISH SWEEPER ACTIVITY IN THE HOT GROWTH BIOTECH

User Image Tangle22 Posted - 1 day ago

$EXEL why it’s down today?

User Image Tangle22 Posted - 5 days ago

$EXEL why it hit 34 when only 375K volume?

User Image UncleStock Posted - 1 week ago

$AVT $EXEL $ZM $UTHR suggested for $RUI US Russell 1000 Index - value screen: https://zpr.io/tey68

User Image Estimize Posted - 1 week ago

Wall St is expecting 0.50 EPS for $EXEL Q4 [Reporting 02/11 AMC] http://www.estimize.com/intro/exel?chart=historical&metric_name=eps&utm_co

User Image Holdem_Foldem Posted - 1 week ago

$AKBA $EXEL has near identical revenue to what is expected of Vafseo… and its a 10B dollar company… that puts akebia at $20 … obviously different types of biotech companies but its very clear the potential of this company

User Image FITZSTOCK2004 Posted - 1 week ago

On 10/16/24 $EXEL engaged LONG from our daily focus list using this breakout price pattern. The Nov 28 calls paid out 218%

User Image Thelonius_Stonk Posted - 1 week ago

$EXEL finally getting loose. grats

User Image Stocksrunner Posted - 1 week ago

🔥 Hot Streak Alert! $EXEL $MUFG and $ACRS are on fire with impressive consecutive gains—10 days straight for $EXEL and $MUFG and 9 for $ACRS! Are they set to keep climbing? Let’s see what Monday brings!

User Image ElijahJobs Posted - 1 week ago

$EXEL Worked out well!

User Image UncleStock Posted - 1 week ago

$EXEL $ZM $UTHR $THC suggested for $RUI US Russell 1000 Index - value screen: https://zpr.io/tey68

User Image UncleStock Posted - 2 weeks ago

$EXEL $UTHR $CORT $NBIX suggested for $BTK US ARCA Biotechnology - value screen: https://zpr.io/tWJwE

User Image JillPeterson308 Posted - 2 weeks ago

$EXEL AITX seems to be capitalizing on every opportunity to innovate, leaving us to wonder what KSCP's next move is.

User Image dick_dasterdly Posted - 2 weeks ago

$EXEL Opened a starter position here yesterday.. Long. I felt that this the prime spot for this to really ramp up. It's in the Roth. And when it's in my Roth , it's gonna stay.

User Image insiderbuyingselling Posted - 2 weeks ago

$EXEL new insider selling: 50000 shares. http://insiderbuyingselling.com/?t=EXEL

User Image Ava_Parker Posted - 2 weeks ago

🚨 MYNZ HUGE PR drop incoming before the Nov 13 meeting 🔥 Someone is pushing these dates of upcoming NEWS 3 biggest stock alert channels announced, might consider to add now, who knows. $CTLT $EXEL

User Image TraderTimes Posted - 2 weeks ago

Our editor Andreas wrote about $EXEL in today's issue of The Trader Times. Read more about his thoughts below!

User Image Darwin_Jos Posted - 2 weeks ago

$EXEL $ITCI MYNZ +10.91% PM LFG, unusually high volume activity last week, apx 30% more than average. 👇😘🚀 This stock may see the last time this price per share PT $5+ 🚀 HUGE PRs drop incoming before the Nov 13 meeting, so compliance is coming—no RS needed. Here is why… 1.Frankie Muniz backing Mainz (yes, the Malcolm guy & NASCAR #33 now repping MYNZ). 2.Petra, ex-Obama advisor, hinted at a big U.S. lab partner. Solid source! 3.Six news hits in 3 weeks—momentum. 4.Already solid in the EU, not new but expanding, with insurance covering their tests. 5.Their test has 88% accuracy vs. EXAS (42%) & GH (20%)—big edge! 6.$1.5M private placement in the bag. 7.CEO teased big plans ahead.

User Image Handbiker Posted - 2 weeks ago

$AUPH hope we have a good week coming up and actually get some clarity on what's going on. Does anyone think that this company is going to try and pull an $EXEL ? I would prefer not to wait 10 years and it's hard to believe that this current management could pull anything like that.

User Image insiderbuyingselling Posted - 2 weeks ago

$EXEL new insider selling: 1162 shares. http://insiderbuyingselling.com/?t=EXEL

User Image jjegglie Posted - 2 weeks ago

$EXEL Wow, congrats to all longs. I got tired of the manic, every quarter rise to 21-23, followed by earnings crash to 18 game and moved along.

User Image bioman4 Posted - 2 weeks ago

$EXEL what a great week! Been here since $15 a share. Sold a few at $24.

User Image LXP Posted - 2 weeks ago

$EXEL whoever has held for the last 18-24 months, congrats. Nice pay day. Wish I would have but I held too long. GL

User Image jeffmeredith Posted - 2 weeks ago

Quick flip of more $EXEL from $31.97 (Oct 30) to $34 = 6.3% gain in two days. $34.45 a new 52 week high here, up 20.3% in a week

User Image StockBraker Posted - 2 weeks ago

$EXEL Okay - Today for sure. 😉😂

User Image Thestocktraderhubzee Posted - 10/31/24

WATCHLIST OCT 31 2024 $QUAD Barrington Research Maintains Outperform on Quad/Graphics, Raises Price Target to $10 $EXEL Guggenheim Maintains Buy on Exelixis, Raises Price Target to $33 $DHI BTIG Maintains Buy on D.R. Horton, Lowers Price Target to $186 $APP BTIG Maintains Buy on AppLovin, Raises Price Target to $202 $GH Bernstein Maintains Outperform on Guardant Health, Lowers Price Target to $35

Analyst Ratings
RBC Capital Outperform Sep 26, 24
JMP Securities Market Outperform Sep 20, 24
UBS Neutral Sep 19, 24
HC Wainwright & Co. Buy Sep 18, 24
Truist Securities Buy Aug 8, 24
JMP Securities Market Outperform Aug 7, 24
RBC Capital Outperform Aug 7, 24
Oppenheimer Outperform Jul 30, 24
Stephens & Co. Equal-Weight May 14, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Haley Patrick J. EVP, Commercial EVP, Commercial Dec 12 Sell 22.93 64,149 1,470,937 307,687 12/14/23
Haley Patrick J. EVP, Commercial EVP, Commercial Dec 12 Option 16.29 50,000 814,500 357,687 12/14/23
Hessekiel Jeffrey EVP, General Counsel.. EVP, General Counsel & Sec Dec 13 Sell 23.01 25,000 575,250 533,345 12/14/23
Hessekiel Jeffrey EVP, General Counsel.. EVP, General Counsel & Sec Nov 30 Sell 22.04 50,000 1,102,000 558,345 12/04/23
Aftab Dana CSO/EVP Disc & Trans.. CSO/EVP Disc & Trans Research Aug 30 Sell 22.47 4,600 103,362 399,943 09/01/23
MORRISSEY MICHAEL President and CEO President and CEO Aug 28 Option 15.31 360,000 5,511,600 945,496 08/30/23
Senner Christopher J. EVP and CFO EVP and CFO Aug 03 Option 14.74 120,000 1,768,800 631,631 08/07/23
Senner Christopher J. EVP and CFO EVP and CFO Aug 03 Sell 20.6 120,000 2,472,000 571,631 08/07/23
Haley Patrick J. EVP, Commercial EVP, Commercial Aug 03 Sell 20.67 30,553 631,531 285,467 08/07/23
Hessekiel Jeffrey EVP, General Counsel.. EVP, General Counsel & Sec Aug 01 Sell 19.63 55,710 1,093,587 571,976 08/03/23
Hessekiel Jeffrey EVP, General Counsel.. EVP, General Counsel & Sec Aug 01 Option 14.74 55,710 821,165 627,686 08/03/23
Hessekiel Jeffrey EVP, General Counsel.. EVP, General Counsel & Sec Apr 03 Option 14.74 13,930 205,328 621,365 04/05/23
Hessekiel Jeffrey EVP, General Counsel.. EVP, General Counsel & Sec Apr 03 Sell 20.01 38,930 778,989 582,435 04/05/23
WYSZOMIERSKI JACK L Director Director Mar 10 Sell 16.61 15,300 254,133 317,467 03/14/23
WYSZOMIERSKI JACK L Director Director Mar 10 Option 6.3 40,000 252,000 332,767 03/14/23
Garber Alan M Director Director Feb 21 Sell 17.49 40,000 699,600 31,417 02/23/23
Garber Alan M Director Director Feb 21 Option 6.3 40,000 252,000 71,417 02/23/23
FELDBAUM CARL B Director Director Feb 09 Sell 17.78 40,000 711,200 18,701 02/10/23
FELDBAUM CARL B Director Director Feb 09 Option 6.3 40,000 252,000 58,701 02/10/23
Haley Patrick J. EVP, Commercial EVP, Commercial Feb 06 Sell 17.37 25,000 434,250 254,414 02/08/23
Haley Patrick J. EVP, Commercial EVP, Commercial Feb 06 Option 4.2 25,000 105,000 279,414 02/08/23
MORRISSEY MICHAEL President and CEO President and CEO Jan 24 Option 4.2 100,000 420,000 440,655 01/26/23
Lamb Peter EVP, Scientific Stra.. EVP, Scientific Strategy & CSO Dec 15 Option 4.2 20,000 84,000 430,958 12/16/22
Lamb Peter EVP, Scientific Stra.. EVP, Scientific Strategy & CSO Dec 15 Sell 15.88 20,000 317,600 410,958 12/16/22
POSTE GEORGE Director Director Nov 29 Sell 16.68 40,000 667,200 193,189 12/01/22
POSTE GEORGE Director Director Nov 29 Option 6.3 40,000 252,000 233,189 12/01/22
Haley Patrick J. EVP, Commercial EVP, Commercial Sep 12 Option 6.21 40,000 248,400 301,591 09/14/22
Haley Patrick J. EVP, Commercial EVP, Commercial Sep 12 Sell 17.94 40,000 717,600 261,591 09/14/22
Senner Christopher J. EVP and CFO EVP and CFO Aug 11 Option 6.21 225,000 1,397,250 670,882 08/12/22
Haley Patrick J. EVP, Commercial EVP, Commercial May 27 Sell 18.21 18,812 342,567 239,818 06/01/22
WILLSEY LANCE Director Director May 12 Option 3.13 40,000 125,200 464,415 05/13/22
WILLSEY LANCE Director Director May 12 Sell 19.65 40,000 786,000 424,415 05/13/22
WYSZOMIERSKI JACK L Director Director Apr 04 Option 3.13 40,000 125,200 279,888 04/06/22
WYSZOMIERSKI JACK L Director Director Apr 04 Sell 23 6,696 154,008 273,192 04/06/22
Haley Patrick J. EVP, Commercial EVP, Commercial Mar 31 Option 6.21 20,000 124,200 279,191 04/04/22
Haley Patrick J. EVP, Commercial EVP, Commercial Mar 31 Sell 22.72 20,000 454,400 269,191 04/04/22
Hessekiel Jeffrey EVP, General Counsel.. EVP, General Counsel & Sec Mar 28 Sell 22 18,000 396,000 605,236 03/30/22
Garber Alan M Director Director Mar 01 Option 3.13 40,000 125,200 52,718 03/03/22
Garber Alan M Director Director Mar 01 Sell 21 21,301 447,321 31,417 03/03/22
Hessekiel Jeffrey EVP and General Coun.. EVP and General Counsel Feb 24 Sell 20 18,000 360,000 555,361 02/28/22
Haley Patrick J. EVP, Commercial EVP, Commercial Feb 25 Sell 19.53 31,238 610,078 198,476 02/28/22
PAPADOPOULOS STELIOS Director Director Feb 22 Sell 19.56 84,515 1,653,113 1,220,036 02/24/22
FELDBAUM CARL B Director Director Feb 22 Option 3.13 20,000 62,600 28,521 02/24/22
FELDBAUM CARL B Director Director Feb 22 Sell 19.49 20,000 389,800 8,521 02/24/22
Haley Patrick J. EVP, Commercial EVP, Commercial Feb 03 Option 1.9 60,000 114,000 305,241 02/04/22
Haley Patrick J. EVP, Commercial EVP, Commercial Feb 03 Sell 17.91 60,000 1,074,600 245,241 02/04/22
Lamb Peter EVP, Scientific Stra.. EVP, Scientific Strategy & CSO Dec 15 Option 6.21 47,500 294,975 410,672 12/17/21
Lamb Peter EVP, Scientific Stra.. EVP, Scientific Strategy & CSO Dec 15 Sell 17.44 47,500 828,400 363,172 12/17/21
Lamb Peter EVP, Scientific Stra.. EVP, Scientific Strategy & CSO Oct 15 Option 6.21 47,500 294,975 458,740 10/15/21
Lamb Peter EVP, Scientific Stra.. EVP, Scientific Strategy & CSO Oct 15 Sell 21.92 47,500 1,041,200 411,240 10/15/21